This Study Tests the Effect of Risankizumab on the Metabolism in the Liver of Five Additional Drugs to Study Possible Drug Interactions in Patients With Psoriasis With or Without Psoriatic Arthritis

• Status: Completed
• Trial end date: 2017-09-22

Summary

To assess the influence of risankizumab on kinetics of cytochrome P450 (CYP) probe drugs as a means of predicting drug-drug interactions.

• Phase: Phase 1

Details

• Lead Sponsor: AbbVie
• Collaborator: Boehringer Ingelheim
• Treatments: Caffeine; Metoprolol; Midazolam; Omeprazole; Warfarin